BillionToOne, Inc.BLLNEarnings & Financial Report
Nasdaq · Health Care · Services-Medical Laboratories
BillionToOne, Inc. is a life sciences and molecular diagnostics firm developing high-precision genetic testing solutions. Its core offerings include non-invasive prenatal tests, oncology diagnostics, and rare disease screening, serving clinical providers and patients mainly in North America.
Revenue
$38.4M
Gross Profit
$20.2M
Operating Profit
$-12.6M
Net Profit
$-14.9M
Gross Margin
52.6%
Operating Margin
-32.9%
Net Margin
-38.8%
YoY Growth
N/A
EPS
$-1.47
BillionToOne, Inc. Q3 FY2024 Financial Summary
BillionToOne, Inc. reported revenue of $38.4M for Q3 FY2024, with a net profit of $-14.9M (-38.8% margin). Cost of goods sold was $18.2M, operating expenses totaled $32.8M.
Key Financial Metrics
| Total Revenue | $38.4M |
|---|---|
| Net Profit | $-14.9M |
| Gross Margin | 52.6% |
| Operating Margin | -32.9% |
| Report Period | Q3 FY2024 |
BillionToOne, Inc. Quarterly Revenue & Net Profit History
BillionToOne, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $83.5M | +117.4% | $5.7M | 6.8% |
| Q4 FY2024 | $45.1M | -53.1% | $-11.5M | -25.5% |
| Q3 FY2024 | $38.4M | — | $-14.9M | -38.8% |
Income Statement
| Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|
| Revenue | $38.4M | $45.1M | $83.5M |
| YoY Growth | N/A | -53.1% | 117.4% |
Balance Sheet
| Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|
| Assets | N/A | $302.1M | $327.5M |
| Liabilities | N/A | $134.3M | $147.6M |
| Equity | $-242.9M | $-251.7M | $-239.5M |
Cash Flow
| Q3 2025 | |
|---|---|
| Operating CF | $13.8M |